Financial disclosure

A Form 1572 is used for investigators to summarise their educational qualifications and experience, and to make a required formal declaration as to their commitment to conduct the study according to the protocol, GCP and the regulations. The sponsor should also collect financial disclosure information from the investigators at this stage, although formal declarations on Form 3455 are not required until the submission of a marketing authorisation application. 

Sec. 312.50 General responsibibties of sponsors Protection of Human Subjects Financial Disclosure by Clinical Investigators Institutional Review Boards (IRBs)... 

User fee cover sheet Financial disclosure information... 

Before commencing a study, the investigator should make a financial disclosure. Most future products will need to benefit from the potential sales of the US market. Even when there is a considerable financial interest in the success of the product, the financial disclosure will not necessarily rule out the investigator s role in the study totally. Most inspectorates are more interested in what is not declared than what is. 

Financial disclosure. Identify funding sources. Support for this Web site will be clearly identified, including the identities of commercial and noncommercial organisations that have contributed funding, services, or material for the site. 

Center for Drug Evaluation and Research (CDER), Center for Biologies Evaluation and Research (CBER). Guidance for Industry, Center for Devices and Radiological Health (CDRH). Draft Guidance for Industry Financial Disclosure by Clinical Investigators, Oct. 26, 1999. 

GCP protocols and amendments Clinical investigation and changes Financial disclosure forms and reports Investigator statement... 

Governance Forces The Public Company Accounting Reform and Investor Protection Act of 2002 (also known as the Sarbanes-Oxley Act, Public Law 107-204) was passed after the well-publicized corporate governance failures starting in 2001.The intent of the act was to strengthen corporate governance and financial disclosure rules under the Security and Exchange Commission s (SEC) rules for publicly traded companies. 

Part 54 — Financial Disclosure by Clinical Investigators, http //www.access.gpo.gov/nara/ cfr/waisidx 01/21 cfr54 01. html. 

Food and Drug Administration (FDA). Financial disclosure by clinical investigators. Title 21 Code of Federal Regulations Parts 54, 312, 314, 320, 330, 601, 807. Federal Register 1998 63(21) 5233-54. 

Includes general enforcement regulations, product jurisdiction, enforcement policy, hearings, protection of human subjects, financial disclosure by clinical investigators, institutional review boards, and good laboratory practice for nonclinical laboratory studies. 

For the US, Module 1 should contain the index for the entire submission, Form FDA 356h, annotated package insert and other labeling, patent information, patent certification, debarment certification, field copy certification, user fee cover sheet, and financial disclosure information. Information on United States patents related to the drug or drug product is to be included in Module 1 of the NDA. If there were waivers for bioquivalency studies or the environmental assessment, these would go in Module 1, since they would refer to specific US regulations. An environmental assessment would be part of... 

The PMA is not accompanied by a statement of either certification or disclosure as required by 21 CFR Part 54 Financial Disclosure by Clinical Investigators. 

In addition, the investigator must complete Financial Disclosure Forms, i.e., FDA Form 3454 (no financial interest) or FDA Form 3455 (financial interest). These forms will confirm any or no financial involvement of the investigator with the company or product they are investigating. 

There are several other key components to trial execution that will require special attention subject recruitment, the informed consent, IRBs/IEC review product accountability, adverse experience and adverse reaction reporting, financial disclosure, and record retention. Each is critical in the overall success of a clinical trial. If one of these is not handled or processed appropriately, the clinical trial will not be used in support of a new product application. Many of these components have been discussed previously in the context of monitoring. Adverse experience and adverse reaction reporting, informed consent, and IRB/IEC are detailed in Chaps. 11 and 20. The remaining key components relative to managing clinical trials will now be addressed. 

---